CGRP monoclonal antibodies in the treatment of migraine - indication criteria and therapeutic recommendations for the Czech Republic

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F20%3AN0000100" target="_blank" >RIV/00064190:_____/20:N0000100 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.14735/amcsnn2020445" target="_blank" >http://dx.doi.org/10.14735/amcsnn2020445</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.14735/amcsnn2020445" target="_blank" >10.14735/amcsnn2020445</a>

Result language
angličtina
Original language name
CGRP monoclonal antibodies in the treatment of migraine - indication criteria and therapeutic recommendations for the Czech Republic
Original language description
Current prophylactic treatment of frequent episodic and chronic migraine is often unsuccessful or associated with adverse events. Calcitonin gene-related peptide (CGRP) is a key peripheral and central patophysiological agent in migraine. Data emerging from trials with monoclonal antibodies suggest that specific blockade of the CGRP pathway may provide an effective and treatment in migraine. At present, precise indication criteria for the administration of these antibodies, required duration of their administration and methods of evaluating their effect, especially on the quality of life, are being determined.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)